New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
08:08 EDTCELG, AGIOAgios Pharmaceuticals enrolls first patient in Phase 1 AG-120 study
Agios Pharmaceuticals (AGIO) announced that the first patient has been dosed in a Phase 1 study of AG-120 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-1 mutation. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein, making it the first targeted therapeutic candidate to treat patients with cancers that harbor the IDH1 mutation. AG-120 is a part of Agios’ global strategic collaboration with Celgene (CELG). The Phase 1, multicenter, open-label, dose-escalation clinical trial of AG-120 is designed to assess the safety and tolerability of AG-120 as a single agent. The study is expected to only enroll subjects with an IDH1-mutant hematologic malignancy, including acute myelogenous leukemia and myelodysplastic syndrome. Key objectives in the study include determining maximum tolerated dose, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity. Disease-specific expansion cohorts will be enrolled at the maximally tolerated or biologically relevant dose.
News For AGIO;CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
20:10 EDTCELGCelgene says patent challenges are baseless, Reuters reports
Subscribe for More Information
July 28, 2015
07:31 EDTCELGCelgene commences tender offer for Receptos
Subscribe for More Information
July 27, 2015
10:40 EDTCELGIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
08:38 EDTCELGAnalysts divided on Biogen following $85 selloff
Subscribe for More Information
July 24, 2015
08:08 EDTCELGCelgene price target raised to $190 from $156 at Canaccord
Subscribe for More Information
July 23, 2015
19:50 EDTCELGCelgene price target raised to $163 from $146 at Cantor
Subscribe for More Information
10:50 EDTCELGCelgene positioned for sustainable growth, says Piper Jaffray
Subscribe for More Information
07:37 EDTCELGCelgene reports Q2 Revlimid sales up 19% to $1.44B
ABRAXANE® sales for the second quarter were $244 million, a 13 percent increase. POMALYST®/IMNOVID® sales for the second quarter were $235 million, an increase of 46%. VIDAZA® sales in the second quarter remained flat year-over-year at $152 million. OTEZLA® sales for the second quarter were $90 million, increasing 49 percent over the first quarter of 2015.
07:37 EDTCELGCelgene raises FY15 adjusted EPS view to $4.75-$4.85 from $4.60-$4.75
Subscribe for More Information
07:32 EDTCELGCelgene reports Q2 adjusted EPS $1.23, consensus $1.20
Subscribe for More Information
July 22, 2015
15:26 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
10:01 EDTAGIOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:28 EDTCELGBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
08:34 EDTAGIOAgios Pharmaceuticals initiated with an Outperform at Northland
Subscribe for More Information
July 21, 2015
11:03 EDTCELGCelgene treatment of pediatric Crohn's disease receives FDA orphan designation
Subscribe for More Information
06:29 EDTCELGCelgene price target raised to $160 from $147 at Piper Jaffray
Subscribe for More Information
06:24 EDTCELGPiper expects 'stronger, bolder' move from Biogen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use